The expression of the APP (amyloid precursor protein), which plays a key role in the development of AD (Alzheimer's disease), is regulated by a variety of cellular mediators in a cell-dependent manner. In this study, we present evidence that p53 regulates the expression of the APP gene in neuroblastoma cells. Transient expression of ectopic p53, activation of endogenous p53 by the DNA-damaging drug camptothecin or Mdm2 (murine double minute 2) depletion decreases the intracellular levels of APP in murine N2aβ neuroblastoma cells. This effect was also observed in primary cultures of rat neurons as well as in SH-SY5Y cells, a human neuroblastoma cell line. Transient transfection studies using plasmids that contain progressive deletions of the 5 region of the gene demonstrate that p53 represses APP promoter activity through a mechanism that is mediated by DNA sequences located downstream of the transcription start site (+ 55/+ 101). Accordingly, expression of a dominant-negative p53 mutant significantly increases the transcriptional activity of the APP promoter. In addition, results obtained in gel mobilityshift assays show that p53 does not bind to the + 55/+ 101 APP region, although it reduces binding of the transcription factor Sp1 (stimulating protein 1). Reduction of Sp1 binding after activation of p53 with camptothecin was also observed in chromatin immunoprecipitation assays. Altogether, our results strongly suggest a mechanism by which p53 precludes binding of Sp1 to DNA, and therefore the stimulation of the APP promoter by this transcription factor.
INTRODUCTION
AD (Alzheimer's disease) is a degenerative disorder of the central nervous system that causes mental deterioration and progressive dementia, and it is accompanied by neuropathological lesions including the presence of senile plaques of which the Aβ (amyloid β-peptide), a hydrophobic 39-43-residue amino acid peptide, is the major component [1, 2] . The Aβ is proteolytically derived from a set of alternatively spliced APPs (amyloid precursor proteins), which are encoded by a single gene located on human chromosome 21. APP plays a central role in AD, and it has been suggested that an increase in the production of this protein might actively contribute to the development of this pathology [3, 4] , probably by inducing the synthesis and deposition of β-amyloid [4, 5] , and the subsequent neurotoxicity [3] . In contrast, it has also been reported that physiological APP levels appear to be involved in neurotrophic events [1] , thus protecting cells against neurodegeneration. APP is ubiquitously expressed in mammalian tissues, and its expression has been proved to be regulated by a variety of cellular mediators, including growth factors [6, 7] , phorbol esters [8, 9] or ligands of the superfamily of steroid/thyroid nuclear hormone receptors [10, 11] .
On the other hand, it has been reported that p53 levels are significantly higher in AD brains than in aged-matched controls [12] , and that p53-associated apoptosis may be directly involved in the development of this pathology. Thus β-amyloid deposits are associated with local neuritic degeneration, and it has been suggested that intracellular β-amyloid would be selectively cytotoxic to human neurons through a p53-associated cell death pathway [13] . In addition, intracellular β-amyloid may directly activate the p53 promoter and the apoptosis process induced by this factor [14] , and a correlation between amyloid accumulation and p53 activation in neurons has also been previously described [15] .
Physiological levels of APP protect neuronal cells against degeneration induced by several apoptosis-controlling factors including p53, an effect that has been proposed to involve the control of p53-mediated gene transactivation [16] . Furthermore, it has been reported more recently that AICD (APP intracellular domain), a secretase-derived β-amyloid intracellular C-terminal domain, controls p53 at a transcriptional level, in vitro and in vivo [17, 18] .
In the present study, we present evidence that ectopic expression of p53, activation of endogenous p53 by treatment with camptothecin or Mdm2 (murine double minute 2) depletion regulates APP expression and specifically decreases the intracellular levels of APP in N2aβ cells, a subclone of the mouse N2a neuroblastoma cell line that has been previously used to analyse the effect of thyroid hormones on APP [10] . The effect of p53 on APP expression appears to be mediated at least in part at the transcriptional level, since transient transfection studies demonstrate that p53 inhibits APP promoter activity. This inhibition requires DNA sequences located within the first exon of the APP gene, between positions + 55 and + 101, a region that nevertheless does not bind p53. In contrast, this fragment contains sequences that bind Sp1 (stimulating protein 1), and p53 appears to inhibit binding of this factor. Taken together, our results suggest a novel mechanism by which the tumour suppressor p53 might decrease APP gene expression by interfering with the activation induced by the transcription factor Sp1, which binds sequences of DNA located downstream of the transcriptional initiation site. DMEM (Dulbecco's modified Eagle's medium) was purchased from BioWhittaker (Verviers, Belgium). FBS (fetal bovine serum) was from Gibco Life technologies Ltd (Paisley, Renfrewshire, Scotland, U.K.). The polyclonal antibody 369A against the cytoplasmic domain of APP [19] was a gift from Dr Samuel E. Gandy (Mount Sinai School of Medicine, New York, NY, U.S.A.). Polyclonal antibody against phospho-p53 was from Cell Signaling Technology. Anti β-catenin antibody was from BD Biosciences. The secondary biotinylated anti-rabbit antibody and the peroxidase-conjugated streptavidin used in Western-blot analysis were from Amersham Biosciences. Camptothecin was from Sigma-Aldrich. siRNA (small interfering RNA) against mRNA encoding Mdm2 was obtained from Dharmacon Research (Lafayette, CO, U.S.A.). Sequence analyses and primer design were performed online by using the nucleotide sequence databases provided by the EMBL (http://www.ebi.ac.uk/embl).
Cell culture
Murine N2aβ neuroblastoma cells were cultured in DMEM supplemented with 10 % (v/v) FBS as previously described [20, 21] . Human SH-SY5Y neuroblastoma cells were cultured in RPMI 1640 medium containing 10 % FBS. Primary cultures of rat cortical neurons were prepared by the laboratory of Dr Diaz-Guerra [Departamento de Fisiologia Endocrina y del Sistema Nervioso, Instituto de Investigaciones Biomedicas (CISC), Madrid, Spain] as described previously [22] . Briefly, the plates were treated with poly-L-lysine (100 μg/ml) and laminin (4 μg/ml) overnight at 37
• C before seeding. Cerebral cortices from 18-day-old rat embryos were dissected and mechanically dissociated in culture medium [Eagle's minimum medium supplemented with 28.5 mM NaHCO 3 , 22.2 mM glucose, 0.1 mM glutamine, 5 % FBS and 5 % (v/v) donor horse serum]. The cells were seeded at a density of 0.3×10 5 cells/cm 2 in the same medium.
Reporter plasmids and expression vectors
The CAT (chloramphenicol acetyltransferase) reporter plasmid containing the − 1099/+ 101 fragment of the human APP gene has been previously described [10, 23] 
Western-blot analysis
Cells transiently transfected 48 h earlier with the p53 expression vector, or treated for 6 h with 10 μM camptothecin, were washed twice with PBS and cellular proteins were extracted by lysis with a buffer (150 mM NaCl, 50 mM Tris, pH 8, 2 mM EDTA, 1 % Triton and 0.1 % SDS) containing the protease inhibitors PMSF (1 mM) and leupeptin (10 μg/ml). The protein content of cells was determined by using the BCA (bicinchoninic acid) assay (Pierce, Rockford, IL, U.S.A.), following the manufacturer's instructions. Equal amounts (40 μg) of cell extracts were then electrophoresed on SDS/8 % polyacrylamide gel and transferred to a PVDF membrane. Non-specific binding was blocked with 5 % (w/v) non-fat dried skimmed milk powder in TBS-T (Tris-buffered saline and 0.1 % Tween 20) for 2-3 h at room temperature (22) (23) • C) and the cellular APP was detected with a 1:1500 dilution of the rabbit polyclonal antibody 369A, raised against the C-terminal domain of APP. After a 1 h incubation at room temperature, the membrane was washed and incubated with a secondary biotinylated anti-rabbit antibody (1:2000) for one additional hour, washed again and finally incubated for 1 h with 1:2000 peroxidase-conjugated streptavidin. All incubations took place at room temperature, and detection by ECL ® (Amersham Biosciences) was carried out according to the manufacturer's indications. The loading control β-catenin was detected with a 1:1500 dilution of a specific antibody obtained from BD Biosciences. Phospho-p53 was detected by using a 1:1000 dilution of the corresponding antibody and a 1:5000 dilution of a secondary biotinylated anti-rabbit antibody.
The apparent molecular mass (kDa) of the detected bands was always determined by using a wide range protein standard (Mark 12 from Novex, San Diego, CA, U.S.A.).
Quantitative real-time PCR assays
Total RNA was extracted using TRI Reagent (Sigma) and mRNA levels were analysed by quantitative RT-PCR (reverse transcription-PCR). RT was performed with 2 μg of RNA by following the specifications of the SuperScript TM First-Strand Synthesis System (Invitrogen Life Technologies). PCRs were performed using an MX3005P instrument (Stratagene) and detected with SYBR Green. Data analysis was done using the comparative C t (threshold cycle value) method and results were corrected with the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA levels, which were not affected by any of the treatments used. The following PCR primers were used: APP, 5 -GGCCCTCGAGAATTACATCA-3 and 5 -GTT-CATGCGCTCGTAGATCA-3 ; GAPDH, 5 -ACAGTCCATGC-CATCACTGCC-3 and 5 -GCCTGCTTCACCACCTTCTTG-3 .
siRNA
Mdm2 expression was lowered using siRNA targeting mouse Mdm2 mRNA. Mdm2 siRNA and a control nontargeting siRNA (L-041098-00 and D-001206-13 respectively) were purchased from Dharmacon Research. Cells were seeded in 6-well plates and the siRNAs were transfected into cells using Lipofectamine TM 2000. RNA was extracted after 72 h and APPmRNA levels were then analysed by using quantitative RT-PCR.
EMSAs (electrophoretic mobility-shift assay)
Synthetic oligonucleotides containing the + 55 to + 101 sequence of the human APP promoter or a consensus p53-binding site [25] were end-labelled with [ 32 P]ATP using T4-polynucleotide kinase and then incubated for 20 min at 22-23
• C with either nuclear extracts obtained from p53-transfected cells or with in vitro translated p53 and/or recombinant Sp1 proteins. Nuclear extracts, obtained by the method of Andrews and Faller [26] , or p53 and Sp1 were incubated on ice for 15 min in a buffer (20 mM Tris/HCl, pH 7.5, 75 mM KCl, 1 mM dithiothreitol, 5 μg/ml BSA and 13 % glycerol) containing 3 μg of poly(dI-dC)·(dI-dC), and then for 15-20 min at room temperature with approx. 70 000 cpm of the double-stranded labelled oligonucleotide.
For competition experiments, a 25-or 50-fold excess of unlabelled probe, the oligonucleotide containing the consensus sequence for p53 binding or an unrelated DNA was added together with the nuclear extracts to the binding reaction mixture.
For gel retardation assays with p53 and Sp1, cDNA for p53 was transcribed and translated in vitro with the TNT kit (Promega) by following the manufacturer's recommendations, and the Sp1 recombinant protein was obtained from Promega. In these assays, an unprogrammed reticulocyte lysate was used as a control for non-specific binding.
DNA-protein complexes were resolved on 7 % non-denaturating polyacrylamide gels containing 0.5 % TBE (Tris/borate/ EDTA; 1 × TBE = 45 mM Tris/borate and 1 mM EDTA) buffer, and the gels were dried and autoradiographed at − 70
• C.
ChIP (chromatin immunoprecipitation) and PCR amplification
For ChIP assays, cells were fixed with formaldehyde, lysed and subsequently sonicated. Twenty 30 s bursts of sonication were applied with 30 s pauses to avoid overheating. Chromatin was precipitated with 2 μg of antibodies against Sp1 (Santa Cruz Biotechnology), p53 (Cell Signaling Technology), or a control IgG, purified and subjected to PCR analysis. Primers used to detect binding to the − 99 to + 213 region of the APP gene were as follows: 5 -AGGCTCCGCTAGGGGTCTCTG-3 (forward) and 5 -CCTCCAGAGCCCGAACCGTCC-3 (reverse).
Statistics
Unless otherwise indicated, all the data points are the mean for two independent experiments performed in duplicate. The significance of the differences was calculated with the Student's t test and is indicated in the Figures with an asterisk (*) (P < 0.05).
RESULTS

Effects of p53 on cell-associated APP isoforms
Cells were transiently transfected with an expression vector for p53, or with a control non-coding vector. The cell-associated APP isoforms were detected 48 h later by Western-blot analysis using the polyclonal antibody 369A. Previous to that, we first confirmed that transfection with the expression vector for p53 is actually followed by an increase in the activation of this transcription factor. As shown in Figure 1 (A), the levels of P-p53 (phosphorylated p53) were significantly higher in lysates obtained from p53-transfected cells. In addition, transient expression of p53 induces a reproducible decrease in the levels of intracellular APP.
As previously reported [10, [27] [28] [29] , the various bands observed in the Western blots represent the mature and immature forms of the three major APP isoforms, APP 770 , APP 751 and APP 695 , which result by alternative splicing from the APP gene. The faster migrating bands represent immature APP and the slower migrating bands the mature isoforms. A densitometric quantification of the total bands is illustrated in Figure 1 (B) and clearly shows that p53 significantly reduces the total level of APP isoforms.
Depletion of Mdm2 decreases APP gene expression
The inhibitory effect of the tumour suppressor p53 on APP gene expression was also analysed in cells depleted of Mdm2, the major negative regulator of p53 in cells. Mdm2 acts as an E3 ligase to ubiquitinate p53 and drive its proteasomal degradation. Thus knockdown of Mdm2 should be followed by a significant increase in cellular p53, and therefore by a reduced expression of APP in the cells. To prove this, cells were depleted of Mdm2 by means of siRNA. At 72 h after transfection, RNA was extracted and the Mdm2 and APP mRNA levels were analysed by using quantitative RT-PCR. Results are shown in Figure 2 . As expected, Mdm2 mRNA levels were drastically reduced (Figure 2A ), p53 was accumulated in the cells ( Figure 2B ) and APP mRNA levels were significantly reduced ( Figure 2C ) in cells exposed to 30 nM Mdm2 siRNA, thus confirming the inhibitory effect of p53 on APP expression.
Activation of p53 by camptothecin reduces APP expression
To further confirm that p53 activation reduces APP expression, we also analysed the influence of the topoisomerase-1 inhibitor camptothecin, a DNA-damaging agent that induces a strong accumulation and activation of p53 [31, 32] , on APP levels. Cells were incubated for 6 h in the presence or absence of 10 μM camptothecin, and the levels of activated (phosphorylated) p53, APP and β-catenin (as a loading control) were determined by Western-blot analysis. The results obtained are illustrated in Figure 3 . As expected, camptothecin induced a strong activation of endogenous p53 that was accompanied by a marked decrease in the levels of intracellular APP, an effect that was even more evident than that induced by p53 transfection (Figure 1) . Additionally, the effect of camptothecin on APP mRNA levels was also analysed by quantitative real-time PCR. APP mRNA was significantly reduced in camptothecin-treated cells, thus confirming that activation of p53 indeed leads to a reduced expression of the APP gene.
Moreover, to confirm whether or not these results obtained in N2a cells, a tumour cell line of murine origin, can be replicated in primary cultures and also in samples of human origin, we have analysed the effect of camptothecin in primary cultures of rat cortical neurons, as well as in SH-SY5Y human neuroblastoma cells. As shown in Figure 4 , the results were in both cases very similar to those obtained in N2a cells, thus discarding a cell-typespecific response.
p53-mediated repression of APP promoter activity
Transient transfection assays were carried out to determine whether or not activation of p53 affects the transcriptional activity of the APP gene in neuroblastoma cells. N2aβ cells were transiently co-transfected with a chimaeric plasmid containing the − 1099 to + 101 bp fragment of the APP gene linked to the CAT reporter gene, and an expression vector for p53, a dominantnegative p53 mutant, or an empty non-coding vector. Cells were collected 48 h later, and CAT activity was determined. As shown in Figure 5 , reporter activity was significantly inhibited in p53-transfected cells and increased in those cells transiently expressing the dominant-negative p53 mutant, thus demonstrating that p53 indeed represses the transcriptional activity of the APP gene.
Identification of the DNA region mediating the repression of APP promoter activity by p53
To map the DNA sequences involved in the p53-induced response, progressively deleted fragments (− 1099, − 487, − 307, − 15 and + 55) of the APP promoter were linked to the upstream region of the CAT gene and transfected into N2aβ cells. As shown in Figure 6(A) , the negative effect of p53 was maintained even in cells transfected with the shortest (+ 55/+ 101 bp) fragment, which only contains sequences located in the first exon of the gene. In addition, we also analysed the effect of p53 in cells cotransfected with a − 15 to + 101 promoter fragment either wildtype or mutated in positions 81-84 (AACT instead of GGGC) or 86-90 (AACTC instead of GAGCA), which correspond to the proposed p53 responsive region. As shown in Figure 6 (B), the inhibitory effect of p53 was observed in cells expressing the wild-type fragment but not in cells transfected with the mutant constructs. Altogether, these results suggest the existence of a p53 response element located downstream of the transcription start site of the gene. To further confirm that sequences located within the + 55 to + 101 bp fragment mediate the effect of p53 on the APP promoter activity, the cells were transiently cotransfected with the + 55 to + 101 bp fragment of the APP gene and an expression vector for p53, a p53 dominant-negative mutant, or an empty non-coding vector. As shown in Figure 7 , CAT activity determined 48 h later was significantly inhibited in p53-transfected cells and increased in those cells transiently expressing the dominant-negative mutant, thus demonstrating that this DNA fragment indeed mediates the repression of APP promoter activity by p53. Of interest, a computer-assisted study revealed that the + 55/+ 101 responsive fragment that as previously reported contains a Sp1-binding site [21] also contains a sequence that largely resembles a half-site of the consensus core sequence established for the p53-binding site [25, 30] . Despite the results presented in the previous Figures, this fragment was unable to bind p53 as proved by gel mobility-shift assays performed with a radiolabelled probe containing the + 55 to + 101 responsive sequence of the APP gene and nuclear extracts obtained from p53-transfected cells or in vitro translated p53. Unexpectedly, no bands compatible with p53-containing mobility complexes were detected in any of the samples analysed. As shown in Figure 8(A) , the retarded bands obtained in a representative assay carried out with nuclear extracts were specifically competed by an excess of unlabelled probe. However, they were not displaced by competition with an unrelated oligonucleotide or in the presence of an oligonucleotide containing the consensus p53-binding site 5 -AGCTTGAACATGTCCCAACATGGTGA-3 [25, 30] . Furthermore, as illustrated in Figure 8 (B), p53 binds very efficiently to the oligonucleotide containing the consensus p53-binding site. However, no specific bands compatible with p53-containing complexes were detected when the radiolabelled + 55/+ 101 probe was exposed to in vitro translated p53, whereas as expected [21] a specific retarded band running in a position compatible with an Sp1-containing complex was detected in assays performed with recombinant Sp1. Remarkably, although p53 does not bind to this fragment, it was very effective in decreasing the binding of Sp1 to this region of the APP gene. The intensity of that band was clearly reduced in the presence of p53, thus suggesting a mechanism in which p53 decreases the accessibility of Sp1 to DNA, and consequently the constitutive stimulation of the APP promoter induced by this factor. In addition, it should be mentioned that the mobility of the Sp1-associated band was not altered in the presence of p53, thus discarding 'in vitro' binding of a p53-Sp1 complex to the Sp1-binding site.
The effect of p53 on 'in vivo' binding of Sp1 to the APP gene was analysed in ChIP assays performed in cells treated with camptothecin to activate endogenous p53. As shown in Figure 8 (C), binding of p53, which was essentially undetectable in control cells, was increased in camptothecin-treated cells. In addition, binding of Sp1 to the APP responsive region was markedly decreased after camptothecin-induced p53 activation, confirming the reduction of Sp1 binding observed in the in vitro assays.
DISCUSSION
In this paper, we present evidence that activation of the tumour suppressor p53 decreases the intracellular APP levels in a murine neuroblastoma cell line. Transient expression of p53 results in a reliable increase in the cell content of total and P-p53 that in turn generates a decrease in the intracellular levels of APP isoforms. This effect of p53 on APP was confirmed in cells depleted of Mdm2, a negative regulator of p53, and also in cells exposed to the DNA-damaging agent camptothecin, which activates the endogenous p53. Furthermore, the inhibitory effect of p53 activation on APP expression has been proved to occur not only in murine N2aβ cells, but also in neuronal primary cultures and in neuroblastoma cells of human origin, thus discarding a potential cell-type-specific response. Our results together with the increase in p53 levels observed in AD brain [12, 33] suggest a role for this protein in AD.
The reduction of intracellular levels that follows the p53 activation could be secondary to a p53-mediated reduction of the transcriptional activity of the APP gene, and this possibility has been actually proved in transient transfection assays performed with a CAT reporter plasmid containing the − 1099/+ 101 fragment of the human APP gene. Transient expression of p53 significantly reduces CAT activity, whereas expression of a dominant-negative mutant of p53 increases activity above that observed in control cells.
Additional assays carried out with pBL-CAT plasmids containing progressive deletions of the APP promoter showed a mechanism of p53 repression mediated by DNA sequences located downstream of the transcription initiation site, in the + 55/+ 101 region of the APP gene. Surprisingly, this region was unable to bind p53, suggesting that, as reported by other repressed promoters lacking a p53 consensus binding site [34] , the repressive effect of this protein could be mediated by a functional interaction with other specific DNA-binding factor(s) that stimulate the promoter through those sequences. In this respect, we have previously reported that the basal transcription factor Sp1 can stimulate APP promoter activity by binding to sequences located in the region of the gene responsible for the effect of p53 [21] , and the existence of a physical interaction between p53 and Sp1 has also been demonstrated [35, 36] . The tumour suppressor p53 appears to co-operate with Sp1 in the activation of several promoters, such as p21, hTERT (human telomerase reverse transcriptase) or IGF-IR (insulin-like growth factor 1 receptor) [37] [38] [39] . However, it has not yet been clarified how that interaction may contribute to control of promoter activity. As reported previously, Sp1-p53 complexes could bind to Sp1-recognition sites in the promoters of different genes [40] . Nevertheless, it has also been reported that interaction of both transcription factors may result in a reduced ability of Sp1 to bind to DNA [41] .
Our results demonstrate that although p53 does not bind directly to the + 55/+ 101 region of the APP gene, it indeed decreases the binding of Sp1 to that region of DNA, thus suggesting a mechanism involving a functional interaction between the tumour suppressor p53 and the basal transcription factor Sp1. Moreover, immunoprecipitation of fragmented chromatin with an anti-p53 antibody reflects the presence of this factor in the protein complex associated with the responsive APP region. Therefore p53 may affect the expression of APP by interacting with Sp1 and/or other unidentified factors, which would mediate its recruitment to chromatin.
Altogether, these results open a new and interesting link between a neurodegenerative pathology and the tumour suppressor p53. Results obtained from in vivo and in vitro models have previously demonstrated that p53 plays an important role in the neuronal death induced by the Aβ in AD brains. It has been described that Aβ 1− 42 activates the p53 promoter, thus inducing p53-dependent apoptosis and neurotoxicity [13] [14] [15] . On the other hand, APP appears to have a dual function in this pathology, since it can prevent neuronal apoptosis by inhibiting p53 activation [16] , but it can also contribute to neurodegeneration if overexpressed [3, 4] . In the present study, we demonstrate that p53 activation represses APP expression and that therefore this tumour suppressor could also play two different and opposite functions in the neurodegenerative processes that characterize AD. According to our results, p53, a transcription factor that induces neuronal apoptosis, could also play a positive role in preventing AD since it can reduce APP expression and therefore the production and accumulation of Aβ 1− 42 , the most neurotoxic isoform of the Aβ [13] .
In summary, our results suggest that in addition to the previously reported function of p53 in the Aβ-induced neurotoxicity, this protein could also reduce the Aβ 1− 42 generation by decreasing APP gene expression. These functions may very likely depend on the cellular levels of p53, and it is evident that new experiments should be performed to fully understand the role of this protein in AD and the precise mechanisms that mediate the repression of APP by p53.
